{"id":"W3005555374","doi":"10.1097/01.hs9.0000563932.34778.38","title":"PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Carfilzomib; Internal medicine; Refractory (planetary science); Dexamethasone; Oncology; Phases of clinical research; Gastroenterology; Multiple myeloma; Lenalidomide; Adverse effect; Pharmacology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002116852,0.00193044,0.001538498,0.0006527154,0.0005532467,0.0009807714,0.001124745,0.001245999,0.005855421],"category_scores_gemma":[0.0007005619,0.0007064487,0.001284709,0.0004155419,0.0008115256,0.0007989925,0.0004714756,0.003047301,0.001170205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001150446,"about_ca_system_score_gemma":0.002367337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001298717,"about_ca_topic_score_gemma":0.003773423,"domain_scores_codex":[0.9995137,0.0002551053,0.00002102538,0.0000671089,0.00006433202,0.00007875571],"domain_scores_gemma":[0.9994357,0.00006883741,0.00009227457,0.00004048843,0.0000445329,0.0003181844],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4906806,0.1751243,0.01201758,0.00160683,0.002148243,0.0005761239,0.0006158485,0.005294954,0.1181133,0.0007024898,0.01130659,0.1818131],"study_design_scores_gemma":[0.494006,0.4815563,0.01124186,0.00003767633,0.0004422988,0.0004707874,0.00006633302,0.001293903,0.0057821,0.0002518917,0.004819438,0.00003137195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987849,0.001725042,0.0007611184,0.0008188199,0.0001180287,0.004958813,0.00148272,0.0001751073,0.002111435],"genre_scores_gemma":[0.975611,0.002407174,0.003922016,0.001661501,0.0002021863,0.005488329,0.004158848,0.00007228004,0.006476627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005855421,"threshold_uncertainty_score":0.01958829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02940570002004456,"score_gpt":0.328572253292662,"score_spread":0.2991665532726175,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}